Key Commercial Pillars
LOUHI’s exceptional commercial value and appeal to investors are driven by the attractive commercial factors:
-
Massive & Growing Global Demand Nontuberculous Mycobacterial (NTM) lung disease represents an attractive, high-value therapeutic area. The Total Addressable Market (TAM) is currently valued at over $15 billion annually and is projected to reach $25 billion by 2033 (CAGR 6.7%)¹. The US, Europe, and Japan constitute approximately 70–80% of this uniform, high-paying demand¹,².
-
Compelling Value-Based Economics A single NTM patient currently creates an extra $44,500 annual financial burden on the healthcare system, driven heavily by prolonged hospital stays and specialized management³. By breaking the bacteria’s protective shield, LOUHI enables shorter, more compliance-friendly treatments that cut these costs directly at the source—offering an economically compelling case for healthcare payers and insurance providers.
-
Accelerated Pathway to Market NTM serves as our primary beachhead indication. Because it is classified as a rare disease, it qualifies for a more streamlined, cost-effective clinical pathway and potential FDA Orphan Drug Designation. This translates into smaller clinical trials, fast-track approval, and up to 7 years of market exclusivity without generic competition. Furthermore, the LOUHI solution is well-positioned to leverage emerging global funding programs and regulatory AMR (Antimicrobial Resistance) pull-incentives.
-
Platform Versatility & Scalability Establishing clinical proof-of-concept in NTM unlocks a highly scalable, multi-species platform. The same underlying biofilm disruptor mechanism can be expanded to massive block-buster indications, including Pseudomonas aeruginosa infections in cystic fibrosis and Tuberculosis, vastly expanding the long-term commercial upside.
LOUHI Commercialization Roadmap
The LOUHI project follows a structured, milestone-driven pathway to transform advanced biomedical research into a high-growth clinical-stage venture. Our strategic roadmap ensures that scientific de-risking and commercial preparations advance hand-in-hand. Following the current R2B phase (2026–2027), our primary objective is to execute a corporate spin-off, secure seed funding, and advance the technology into human clinical trials.
Partner with Us
LOUHI is an advanced Research to Business (R2B) project funded by Business Finland at Tampere University. Currently in the pre-clinical phase, we are actively preparing for our next major milestone: executing a corporate spin-off and entering clinical trials right after the conclusion of the R2B project phase. To accelerate this transition, we are seeking commercial partners, co-development opportunities, and venture capital investors to shape the future of infectious disease treatment.